Investing Profile

Liam Ratcliffe

InvestorVCAngel
General Partner at New Leaf Venture Partners
accessbio-tech.comNew York, New York
Photo of Liam Ratcliffe, General Partner at New Leaf Venture Partners

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Pfizer Network
86 CONNECTIONS
University of Cape Town Network
50 CONNECTIONS
University of Cape Town Network
50 CONNECTIONS
Access Industries Network
12 CONNECTIONS
cb
$100K - $5.0M
$1.5M
22
$200M
CompanyStageDateRound SizeTotal Raised
Margin.
Pre SeedJan 2026$1M
$1M
Co-investors: Greg Maffei (BANN Ventures), Bill Ackman
Draig Therapeutics
Series AJun 2025$140M
$140M
Co-investors: Colleen Cuffaro (Canaan Partners)
Climb Bio
Series BMay 2021$60M
Series AMar 2021$80M
$260M
Co-investors: Andrew Levin (RA Capital Management), Ohad Hammer (Pontifax Venture Capital)
Shoopy
SeedFeb 2021$250K
$250K
Passage Bio
Series BSep 2019$110M
Series AFeb 2019$120M
$230M
Co-investors: Stephen Squinto (J.P. Morgan Asset Management), Carl Gordon (OrbiMed Advisors), Tom Woiwode (Versant Ventures), Patrick Heron (Frazier Healthcare Partners)
CuraSen Therapeutics
Series AOct 2018$55M
$55M
Arvinas
Series CApr 2018$55M
Series BOct 2015$42M
$140M
Co-investors: Colleen Cuffaro (Canaan Partners), Tim Shannon (Canaan Partners), Kush Parmar (5am Ventures), Martin Alexander Gershon (Endeavor Venture Funds), Daniel Wagner (Connecticut Innovations), Stephen Squinto (J.P. Morgan Asset Management), Andrew Levin (RA Capital Management), Jakob Loven (Nextech Invest Ltd.)
Aptinyx
Series BDec 2017$70M
Series AMay 2016$65M
$140M
Co-investors: Adam Koppel (Bain Capital Ventures), James N. Topper (Decheng Capital)
Snr VP, Pfizer Global Research and Development PfizerPresent
Managing Director New Leaf Venture PartnersPresent
Head of Biotechnology Access IndustriesPresent
General Partner New Leaf Venture PartnersPresent
University of Cape Town MBChB Medicine
University of Cape Town PhD immunology
Sign in with Google →
Sign in with Google →